<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817958</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0160/1406</org_study_id>
    <secondary_id>AFU-GETUG 25</secondary_id>
    <nct_id>NCT02817958</nct_id>
  </id_info>
  <brief_title>Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis (AFU-GETUG 25)</brief_title>
  <acronym>MEGACEP</acronym>
  <official_title>Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Squamous cell carcinoma of the penis is a rare tumor in Europe, whose prognosis and survival
      are influenced by metastatic lymph node involvement. Its frequency in France is estimated at
      less than 1% of human cancers. This spread follows a sequential process via the superficial
      and deep inguinal lymph nodes and then to the pelvic lymph nodes before metastatic
      dissemination.

      The management of inguinal areas is the cornerstone of penile cancer. It is curative in about
      80% of patients with 1 or 2 inguinal metastases. 5-years overall survival was on average 85%
      for pN0 patients and 40% for pN + patients. For pN + patients, 5-years overall survival was
      70 to 80% for pN1 (only 1 lymph node invasion), and 30 to 40% for pN2 and 0 to 10% for pN3.

      The risk of local recurrence is 5-10% for pN0 and 20-30% for pN + after local treatment by
      lymphadenectomy alone without chemotherapy. The average time to recurrence was 10 months.
      Disease-free survival at 5 years is 75-85% for pN0 and 30-45% for pN +. Its indication
      depends on clinical examination (presence or absence of lymph nodes palpated) and the risk of
      nodal disease (≥ pT1bG2).

      Currently, a fine needle biopsy is the best clinical diagnosis method because it is a simple,
      low risk and possible in consultation. When the result is positive, it allows an early
      dissection. Single or double fine needle biopsy will be used in cN + patients. For patients
      at risk of lymp nodes involvement (cN0 and ≥ pT1B or G2), the sentinel node diagnosis may be
      followed by modified or bilateral lymphadenectomy.

      Although lymphadenectomy alone has a curator action, it sometimes remains insufficient in
      patients with metastatic lymph node involvement. Therefore it seems important to develop a
      multimodal approach in the management of these patients in order to increase the response
      rate to treatment and survival.

      From a Phase II trial conducted on 30 patients, the combination TIP (paclitaxel, ifosfamide
      and cisplatin) appears to have an efficacy / toxicity acceptable.

      The TIP protocol has therefore been chosen for this trial as adjuvant or neo-adjuvant
      treatment in patients with high risk of lymph nodes involvement (cN0 and ≥ pT1B or G2), and
      with inguinal mobile palpated lymph nodes (cN +) respectively, after lymph nodes involvement
      proven (pN +).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival without locoregional lymph node recurrence</measure>
    <time_frame>24 months</time_frame>
    <description>checked by inguinal ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate for patients in neoadjuvant chemotherapy</measure>
    <time_frame>6 months</time_frame>
    <description>lack of residual tumor post surgical histopathology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without locoregional lymph node recurrence</measure>
    <time_frame>3 years</time_frame>
    <description>time between inclusion and locoregional recurrence or last evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without metastasis</measure>
    <time_frame>3 years</time_frame>
    <description>time between inclusion and the date of occurrence of metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific survival</measure>
    <time_frame>3 years</time_frame>
    <description>time between inclusion and date of death from penile cancer or treatment-related complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>time between inclusion and the death regardless of cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>CTCAE (Common Terminology Criteria for Adverse Events), v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>questionnaire EORTC QLQ-C30 v3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Penile Cancer</condition>
  <condition>Squamous Carcinoma</condition>
  <arm_group>
    <arm_group_label>A-Adjuvant Chemotherapie TIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphadenectomy (+/- sentinel node) + adjuvant chemotherapie TIP modified bilateral lymphadenectomy 4 cycles every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-Neoadjuvant Chemotherapie TIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fine needle biopsy or sentinel node + neoadjuvant chemotherapie TIP followed by a lymphadenectomy modified bilateral lymphadenectomy 4 cycles every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapie TIP</intervention_name>
    <description>Paclitaxel, ifosfamide and cisplatine</description>
    <arm_group_label>A-Adjuvant Chemotherapie TIP</arm_group_label>
    <arm_group_label>B-Neoadjuvant Chemotherapie TIP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. penile tumor histologically proven whatever the initial treatment of penile tumor:
             amputation or conservative surgery or brachytherapy,

          2. Mobile palpated lymph nodes (stage cN1 and cN2) whatever the T stage, Or If no
             palpated lymph nodes (cN0), patients with nodes involvement risk ≥pT1b and / or Grade
             2

          3. Metastatic lymph node involvement

          4. Patients M0 or Mx,

          5. Age≥18 ans,

          6. ECOG 0-1,

          7. Leucocytes ≥ 1.5 G/L,

          8. Hemoglobin ≥ 9 g/dL,

          9. Platelets ≥100 000/mm3,

         10. Normal calcemia and kaliemia,

         11. AST and ALT ≤ 1.5 LNS ; total bilirubin ≤ 1.5 LNS (3 LNS in case of Gilbert disease);
             PAL &lt; 2 LNS,

         12. Creatinine clearance ≥ 60 mL/mn (MDRD method),

         13. FEVG &gt; 50%,

         14. Patients having received, read the information note and signed consent,

         15. Reproductive age patients agreeing to use two methods of birth control (one for the
             patient and one for the partner) for the duration of the study and for 6 months after
             the last dose of treatment,

         16. Patients able to comply with the protocol requirements (scheduled visits, treatment
             plan, clinical, paraclinical, biological and other procedures of the Protocol)

         17. Patients undergoing a social security scheme.

        Exclusion Criteria:

          1. Fixed inguinal lymph nodes (cN3)

          2. Iliac lymph nodes (cN3)

          3. Patients pN3

          4. prior chemotherapy for squamous cell carcinoma of the penis,

          5. Against-indication for chemotherapy or known hypersensitivity to cisplatin, ifosfamide
             or paclitaxel,

          6. Patients treated with phenytoin,

          7. Patients with hearing loss&gt; Grade 1 (CTC-AE V4.03)

          8. Patients with cardiopulmonary disease-indicating against overhydration,

          9. History of cancer within 5 years prior to inclusion in the trial other than cutaneous
             basal cell,

         10. Patient received a live attenuated vaccine within 30 days prior to inclusion,

         11. Patients already included in another clinical trial or receiving an experimental
             treatment within 30 days prior to inclusion in the trial,

         12. Patients deprived of their lyberty or under court protection including guardianship,

         13. Severe systemic disease or uncontrolled or any other chronic or acute illness that is
             incompatible with the patient's participation in the trial according to investigator,

         14. immunocompromised patients including with known seropositivity (HIV),

         15. Patients with mental impairment which prevents the understanding of the protocol or
             having a psychological state, family, sociological or geographical conditions that
             would not allow compliance with the protocol and the planned follow-up or any
             condition which, according to the investigator, would prevent participation patient
             tested. These conditions should be assessed before inclusion of patients.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme Rigaud, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra PELISSIER</last_name>
    <phone>+33(0)144235568</phone>
    <email>s-pelissier@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICO-Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle BOMPAS, Doctor</last_name>
      <phone>+33(0)2 41 35 27 00</phone>
      <email>emmanuelle.bompas@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chr Besancon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tristant MAURINA, Doctor</last_name>
      <phone>+33(0)3 81 66 93 67</phone>
      <email>t1maurina@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital SAINT ANDRE</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amaury DASTE, Doctor</last_name>
      <email>amaury.daste@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre FRANCOIS BACLESSE</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence JOLY, Prof</last_name>
      <phone>+33 2 31 45 50 02</phone>
      <email>f.joly@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru Gabriel Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent GUY, Professor</last_name>
      <phone>+33(0)4 73 75 14 97</phone>
      <email>lguy@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien DESCAZEAUD, Professor</last_name>
      <phone>+33(0)5 55 05 80 15</phone>
      <email>aurelien.descazeaud@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude FLECHON, Doctor</last_name>
      <phone>+33(0)4 78 78 26 43</phone>
      <email>aude.flechon@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Etienne TERRIER, Dr</last_name>
      <phone>+33 4 72 67 88 01</phone>
      <email>jean-etienne.terrier01@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenaelle GRAVIS, Doctor</last_name>
      <phone>+33(0)4 91 22 37 40</phone>
      <email>gravisg@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent MASSARD, Dr</last_name>
      <phone>+33 3 23 59 84 61</phone>
      <email>v.massard@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Urologique- Chu Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme RIGAUD, Professor</last_name>
      <phone>+33(0)2 40 08 39 10</phone>
      <email>jrigaud@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Du Gard - Centre Oncogard</name>
      <address>
        <city>Nîmes</city>
        <zip>300029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angélique CHAPELLE, Doctor</last_name>
      <phone>+33(0)4 30 06 10 14</phone>
      <email>a.chapelle@oncogard.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane CULINE, Professor</last_name>
      <phone>+33(0)1 42 49 42 47</phone>
      <email>stephane.culine@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian PFISTER, Professor</last_name>
      <phone>+33(0)2 32 88 81 63</phone>
      <email>christian.pfister@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO-René Gauducheau</name>
      <address>
        <city>saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle BOMPAS, Doctor</last_name>
      <phone>+33(0)2 40 67 97 00</phone>
      <email>emmanuelle.bompas@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BARTHELEMY, Doctor</last_name>
      <email>philippe.barthelemy@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loic MOUREY, Doctor</last_name>
      <phone>+33(0)5 31 15 51 67</phone>
      <email>mourey.loic@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inguinal lymph nodes</keyword>
  <keyword>penile cancer</keyword>
  <keyword>squamous</keyword>
  <keyword>TIP chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Penile Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

